Waters Co. (NYSE:WAT) Stock Position Boosted by TD Private Client Wealth LLC

TD Private Client Wealth LLC grew its stake in shares of Waters Co. (NYSE:WAT) by 22.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 993 shares of the medical instruments supplier’s stock after buying an additional 182 shares during the quarter. TD Private Client Wealth LLC’s holdings in Waters were worth $368,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Bank of Jackson Hole Trust bought a new stake in Waters during the fourth quarter worth approximately $34,000. Fortitude Family Office LLC increased its position in shares of Waters by 235.7% during the 4th quarter. Fortitude Family Office LLC now owns 94 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 66 shares during the period. Steward Partners Investment Advisory LLC raised its stake in shares of Waters by 129.3% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 94 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 53 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Waters by 54.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 125 shares of the medical instruments supplier’s stock valued at $46,000 after buying an additional 44 shares during the period. Finally, R Squared Ltd bought a new position in Waters during the fourth quarter valued at about $63,000. 94.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on WAT shares. Scotiabank upgraded shares of Waters from a “sector perform” rating to a “sector outperform” rating and boosted their price target for the stock from $430.00 to $450.00 in a research report on Thursday, February 13th. UBS Group boosted their target price on shares of Waters from $405.00 to $410.00 and gave the stock a “neutral” rating in a report on Thursday, February 13th. Sanford C. Bernstein upgraded shares of Waters from a “market perform” rating to an “outperform” rating and set a $430.00 target price for the company in a report on Friday, January 10th. JPMorgan Chase & Co. upped their price target on Waters from $380.00 to $390.00 and gave the company a “neutral” rating in a report on Thursday, March 6th. Finally, Bank of America reduced their price objective on Waters from $430.00 to $410.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Eleven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $391.07.

Waters Price Performance

Shares of WAT opened at $373.07 on Tuesday. The business’s 50-day moving average is $390.29 and its 200-day moving average is $371.85. The company has a debt-to-equity ratio of 1.14, a current ratio of 0.94 and a quick ratio of 0.65. The company has a market capitalization of $22.16 billion, a price-to-earnings ratio of 34.83, a P/E/G ratio of 3.79 and a beta of 1.00. Waters Co. has a fifty-two week low of $279.24 and a fifty-two week high of $423.56.

Waters (NYSE:WAT) last released its quarterly earnings data on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share for the quarter, beating the consensus estimate of $4.02 by $0.08. Waters had a net margin of 21.56% and a return on equity of 46.31%. Equities research analysts expect that Waters Co. will post 12.86 EPS for the current fiscal year.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.